The mid adult female doctor reviews her patient's records on her computer in her office.

Clinicians

Choose EndoPredict® Breast Cancer Prognostic Test and make the right decision for your patient.

EndoPredict helps you detect risk of recurrence for ER positive/HER2 negative early-stage breast cancer

Gene expression tests are guiding critical treatment decisions in early‑stage breast cancer. Using genomic testing for breast cancer recurrence, you can avoid under or over treatment and the life-changing impact these choices can have on a woman’s life – now and in years to come.

EndoPredict Breast Cancer Prognostic Test is the most accurate gene expression test for early-stage breast cancer recurrence to help you make treatment decisions for your eligible ER positive/HER2 negative primary invasive breast cancer patients.1,2

Myriad Genetics is committed to illuminating the treatment pathway for every woman

How can the EndoPredict test help you and your patient?

Chemotherapy decisions

EndoPredict predicts the individual chemotherapy benefit for women with ER positive/HER2 negative early-stage breast cancer, so confident treatment decisions can be made with your patients.3

10 year recurrence risk

EndoPredict provides an accurate assessment for risk of breast cancer recurrence within 10 years, allowing you and your patients to make confident systemic therapy decisions together.4

15 year recurrence risk

EndoPredict is the only test able to predict risk of recurrence up to 15 years, allowing you to predict the future and make safe choices with your patients today.5

A concerned female doctor reviews a senior female patient's troubling test results.

Which patients are eligible for the EndoPredict test?

EndoPredict gives important information to guide early treatment decisions for women with invasive primary breast cancer that is:

  • HER2 negative
  • ER positive
  • Lymph node positive or negative
  • Tumour size pT1 to pT3
  • Grade 1 to 3
  • Pre- and postmenopausal

EndoPredict is the ONLY second generation breast cancer recurrence gene expression test validated for premenopausal as well as postmenopausal women.2-8

Evidence you can trust

Learn more about EndoPredict’s superior accuracy and prognostic performance.

Validation

Validated in five prospective-retrospective studies of more than 3,500 patients.2-8

Prospective confirmation

Data released at SABCS 2021 from a prospective randomized phase III study confirm the accuracy and prognostic power of EndoPredict, particularly in node positive patients.9,10

Guidelines

EndoPredict is recommended by many international and national guidelines, including ASCO, NCCN, AJCC, ESMO, St. Gallen, EGTM, AGO, HAS, NICE, SEOM, AIOM, CACA-CBCS, CcO.

Confident decisions across all patient groups

Chemotherapy in premenopausal breast cancer

EndoPredict Breast Cancer Prognostic Test is the only second generation breast cancer recurrence gene expression test validated for premenopausal AND postmenopausal women.2-8

Node positive breast cancer and chemotherapy

EndoPredict Breast Cancer Prognostic Test is the only second generation test with level of evidence 1A9,10 for node positive breast cancer. The test is validated to accurately identify node positive breast cancer patients with true low-risk of cancer recurrence, allowing more of your patients to safely avoid adjuvant chemotherapy.2-8

For node negative patients, EndoPredict correctly identifies a large group at low-risk BUT also classifies high-risk patients who can benefit from chemotherapy.2,5

What does the EndoPredict test report tell me?

EndoPredict Breast Cancer Prognostic Test provides clear, fast and actionable results for every woman with ER positive/HER2 negative early-stage breast cancer.

Learn how to interpret the EndoPredict report

How to order an EndoPredict test

EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.

Find your local lab
Contact your local pathology lab offering EndoPredict. This offers the fastest turnaround time for an EndoPredict test.

Send your sample
You can take tumor samples from a biopsy or surgical specimen and simply send to your local lab. The lab will provide further information on preparing and sending the sample.

Results in days
Once the lab has received your sample, results can be returned within a few days, allowing you and your patient to make important treatment decisions without delay.

References

  1. Sestak, Ivana et al. “Comparison Of The Performance Of 6 Prognostic Signatures For Estrogen Receptor–Positive Breast Cancer“. JAMA Oncology, vol 4, no. 4, 2018, pp. 545-553
  2. Buus, Richard et al. “Comparison Of Endopredict And Epclin With Oncotype DX Recurrence Score For Prediction Of Risk Of Distant Recurrence After Endocrine Therapy“. Journal Of The National Cancer Institute, vol 108, no. 11, 2016, p. djw149
  3. Sestak, Ivana et al. “Prediction Of Chemotherapy Benefit By Endopredict In Patients With Breast Cancer Who Received Adjuvant Endocrine Therapy Plus Chemotherapy Or Endocrine Therapy Alone“. Breast Cancer Research And Treatment, vol 176, no. 2, 2019, pp. 377-386
  4. Filipits, Martin et al. “A New Molecular Predictor Of Distant Recurrence In ER-Positive, HER2-Negative Breast Cancer Adds Independent Information To Conventional Clinical Risk Factors“. Clinical Cancer Research, vol 17, no. 18, 2011, pp. 6012-6020
  5. Filipits, Martin et al. “Prediction Of Distant Recurrence Using Endopredict Among Women With ER+, HER2− Node-Positive And Node-Negative Breast Cancer Treated With Endocrine Therapy Only“. Clinical Cancer Research, vol 25, no. 13, 2019, pp. 3865-3872
  6. Constantinidou, Anastasia, et al. “Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer”. Clinical Cancer Research, vol. 28, no. 20, 2022, pp. 4435–4443
  7. Martin, Miguel et al. “Clinical Validation Of The Endopredict Test In Node-Positive, Chemotherapy-Treated ER+/HER2− Breast Cancer Patients: Results From The GEICAM 9906 Trial“. Breast Cancer Research, vol 16, no. 2, 2014, p. R38
  8. Dubsky, Peter et al. “The Endopredict Score Provides Prognostic Information On Late Distant Metastases In ER+/HER2− Breast Cancer Patients“. British Journal Of Cancer, vol 109, no. 12, 2013, pp. 2959-2964
  9. Simon, Richard et al. “Use Of Archived Specimens In Evaluation Of Prognostic And Predictive Biomarkers”. Journal Of The National Cancer Institute, vol 101, no. 21, 2009, pp. 1446-1452
  10. Penault-Llorca, Frederique et al. “Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of *** (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)“. SABCS 2021, PD-09-08 Spotlight Poster Discussion 9
  11. Vázquez-Juarez, Daniela et al. ”Follow-up of prospective cohort of Mexican premenopausal women with breast cancer who received guided adjuvant treatment with the EndoPredict assay.” SABCS 2021, P4-05-15